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A single application of crude coal tar (CCT) solution (USP) 
to the skin of neonatal rats was shown to induce epidermal 
and hepatic cytochrome P-450(P-450)-dependent monoox-
ygenase activities. To further characterize the induction re-
sponse, in this study we have utilized highly specific mono-
clonal antibodies (MoAb) 1-7-1,2-66-3, and 1-98-1 directed 
against highly purified rat liver P-450s induced by 3-methyl-
cholanthrene, phenobarbital and ethanol, respectively. So-
dium dodecyl sulfate polyacrylamide gel electrophoresis of 
hepatic microsomes prepared from CCT -treated animals 
showed a significant increase in the coomassie blue stainable 
proteins in the P-450 region; however, this was not evident 
in epidermal microsomes. Immunoblot analysis of epidermal 
and hepatic microsomes with MoAb 1-7-1 revealed strong 
immunoprecipitin bands in both tissues. MoAb 2-66-3 
showed significant immunoreactivity only with hepatic mi-
crosomes. Interestingly, CCT treatment resulted in sup-
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pression of immunoreactivity with MoAb 1-98-1 in hepatic 
microsomes. MoAb 1-7-1 and 2-66-3 exhibited concentra-
tion-dependent inhibitory effects in aryl hydrocarbon hy-
droxylase and 7 -ethoxycoumarin-O-deethylase activities in-
duced by CCT application. MoAb 1-7-1 was substantially 
more effective in this respect. Epidermal and hepatic micro-
somes prepared from CCT-treated rats showed significantly 
greater metabolism ofbenzo(a)pyrene (BP). MoAb 1-7-1 and 
MoAb 2-66-3 inhibited BP metabolism in both the tissues. 
However, MoAb 1-7-1 was more inhibitory in this regard as 
compared to MoAb 2-66-3. These studies indicate that topi-
cal application of therapeutic CCT to the skin of neonatal 
rats results in induction of P-450 isozyme c in epidermis and 
isozymes band c in liver, and that this induction is associated 
with the suppression of P-450 isozyme j in liver J Invest Der-
matoI93:40- 45, 1989 
C rude coal tar (CCT) is an extremely complex mixture of chemicals containing multiple polycyclic aromatic hydrocarbons, only a few of which have been rigor-ously characterized [1]. Topical preparations con-taining CCT have been used widely for many dec-
ades in the treatment of various dermatologic disorders, particularly 
psoriasis [2] . The carcinogenic and mutagenic effects of CCT and 
some of its constituent chemicals in experimental systems have been 
well documented [3] . Studies by Saperstein and Wheeler [4] demon-
strated that CCT is mutagenic in vitro and Wheeler et al [5] subse-
quently showed that unidentified mutagenic substance(s) are 
present in the urine of patients undergoing Goeckerman therapy of 
psoriasis. Studies in human subjects by Clonfero et al [6] identified 
the mutagenic components in the urine of psoriatic patients and 
suggested that low molecular weight polycyclic aromatic hydrocar-
bons (PAHs) constitute the major components responsible for this 
effect. Recently Schoket et al [7] detected covalent binding ofPAH-
DNA in the lungs of animals following topical application of CCT 
and its components. Studies from our laboratory have shown that 
therapeutic CCT preparations possess tumor initiating activity in 
standard murine skin bioassay systems [8]. 
Most of the PAH themselves are relatively inert biologically and 
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essentially act as precarcinogens that must first undergo metabolic 
activation by the mammalian enzyme systems whereby they are 
converted to their biologically active ultimate carcinogenic metabo-
lites [9]. The first step in the metabolic activation ofPAH is known 
to be dependent on the heme-protein cytochrome P-450 that is the 
terminal oxidase for the monooxygenase system. The P-450 iso-
zymes display different substrate specificities and reactivities toward 
various endogenous and exogenous substrates [10]. Studies during 
the past decade have shown that cutaneous P-450-dependent mono-
oxygenases can metabolize various PAH including benzo(a)pyrene 
(BP) known to be present in CCT [11,12]. Studies from our labora-
tory have shown that application of CCT to the skin of neonatal rats 
resulted in significant induction ofP-450-dependent monooxygen-
ase activities in epidermis and liver [13]. Based on these observations 
we previously suggested that CCT is a mixed type of inducer capa-
ble of inducing more than one type of P-450 [14]. 
Because P-450 catalyzes a variety of reactions it is important to 
characterize the profile ofp-450 induced in response to an inducer. 
This has implications for better understanding of target organ toxic-
ity including chemical carcinogenesis. For example, it is acknowl-
edged that type and amount of P-450 isozymes within a tissue 
determines whether particular substrates are converted to nontoxic 
products or to toxic metabolites [15]. Recently monoclonal antibod-
ies (MoAb) to purified P-450 isozymes have been employed as an 
immunochemical approach to define P-450 isozymes in various 
human and animal tissues [16,17]. In the present study MoAbs 
raised against purified hepatic P-450 were used to assess the profile 
of P-450 isozymes induced by CCT. Our results indicate that topi-
cal application of CCT to rats resulted in the induction of P-450 
isozyme c in epidermis and isozyme band c in liver, and that this 
induction response is associated with the suppression of P-450 iso-
zyme j in liver. 
MATERIALS AND METHODS 
Animals and Treatment Pregnant Sprague-Dawley rats were 
obtained from Holtzman Rat Farm (Madison, WI). Neonatal rats 
were allowed to suckle until the day of the experiment (3 - 5 dafter 
birth) . The advantages of using neonatal rodents for cutaneous 
P-450-dependent metabolic studies are described elsewhere [11]. 
The animals were treated with a single topical application of200 pi 
of CCT solution (USP). Control animals received an identical vol-
ume of acetone. Because of the inherent volatility of CCT and its 
constituents, all experimental animals were housed in a room sepa-
rate from that of control animals. The doses of CCT selected were 
based on maximal induction responses in P-450-dependent aryl hy-
drocarbon hydroxylase (AHH) activity. 
Chemicals 7-ethoxycoumarin and resorufin were purchased 
from Aldrich Chemical Co. (Milwaukee, WI). Bovine serum albu-
min (BP), NADP, and NADPH were purchased from Sigma 
Chemical Co. (St. Louis, MO). 7-ethoxyresorulin was a product of 
Pierce Chemicals. (7 ,1 0-I4C]BP (sp. act. 58.5 mCi/mmol) was pur-
chased from Amersham Searle (Chicago, IL). Prior to use radiola-
beled BP was purified on a silica gel (Partisil 10 p; Waters Asso-
ciates) column with hexane as the eluting solvent, and subsequently 
by reverse-phase HPLC using a DuPont Zorbax ODS column 
(6.2 mm X 20 cm) with methanol and water (19:1, v/v) as the 
eluent. The purity of BP was greater than 99% as judged by high-
pressure liquid chromatography (HPLC). BP metabolite reference 
standards were provided by the Cancer Research Program (Division 
of Cancer Etiology, National Cancer Institute, Bethesda, MO). All 
solvents used were ofHPLC grade and were purchased from Fisher 
Scientific Co. (Fairlawn, NJ). All chemicals and equipment for 
electrophoresis were from Bio-Rad (Rockville Centre, NY). Nitro-
cellulose paper (0.45 pm) was from Schleicher & Schue II (Keen, 
NH), and other immunochemical reagents were from KPIC (Be-
thesda, MD). All other chemicals were obtained in the purest form 
commercially available. 
Preparation of MoAbs MoAb were prepared by the hybridoma 
method of Kohler and Milstein [18] by two of us (SSP, HVG) at the 
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National Cancer Institute, Laboratory of Molecular Carcinogene-
sis. The highly specific MoAb directed toward the 3-MC (P-450c). 
PB (P-450b) and ethanol (P-450j) induced forms of rat liver P-450 
were from clone 1-7-1, 2-66-3 and 1-98-1, respectively, as de-
scribed previously [19-21]. MoAb derived from hybrid cells of 
myeloma cells and spleen from unimmuruzed normal BALB/c mice 
(NBS 1-48-5) were used as controls [19]. 
Preparation of Epidermal and Hepatic Microsomes After the 
desired period of treatment with CCT the animals were killed by 
decapitation, and their skin and livers were removed. In each exper-
iment tissues from 10 animals were pooled for single determina-
tions. Epidermis was separated by incubating whole skin in 0.1 M 
phosphate buffer pH 7.40 containing 10 mM dithiothreitol accord-
ing to the procedure of Epstein et al, as described earlier, and micro-
somes were prepared according to established procedures in the 
laboratory [11]. Microsomal pellets were suspended in buffer A 
(0.1 M potassium phosphate, pH 7.4 containing 10 mM dithiothre-
itol, 10 mM EDTA, and 20% v/v glycerol) and frozen at -170°C 
under liquid nitrogen. Enzyme activities were stable for at least 3 
weeks under these storage conditions. 
Estimation of Microsomal Enzyme Activities AHH activity 
was determined according to the method of Nebert and Gelboin 
[22]. The quantitation of Phenolic BP metabolites was based on 
comparison with the fluorescence of standard 3-hydroxy 
benzo(a)pyrene. 7 -Ethoxyresorufin-O-deethylase (ERD) activity 
was determined according to a slight modification [23] of the 
method of Pohl and Fouts [24]. 7-Ethoxycoumarin O-deethylase 
(ECO) activity was determined according to the method of Green-
lee and Poland [25] as described earlier [11]. p-Nitrophenol hydrox-
ylase (P-NPH) activity was determined by measuring the hydroxyl-
ation of p-nitrophenol to 4-nitrocatechol according to the method 
of Reinke and Moyer [26] as described by Koop [27]. Protein was 
estimated according to Lowry et al [28] using bovine serum albumin 
as a reference standard. For enzyme inhibition studies, the micro-
somal suspension was preincubated for 15 min at 37° C with differ-
ent amounts of the MoAb, and the enzyme activity was determined 
as described above. MoAb 1-48-5 was employed in control incuba-
tions and was found not to effect enzyme activities. 
In Vitro BP Metabolism The incubation mixture in a final vol-
ume of 1.0 ml contained 0.5 mg of epidermal or hepatic micro-
somal protein , 0.10 mmol of phosphate buffer (PH 7.4), 3 pmol of 
MgCI2' and 1.3 pmol of NADPH. For MoAb inhibition studies, 
the microsomal protein was preincubated for 15 min at 37°C with 
200).l.g of MoAb 1-7-1 or MoAb 2-66-3. The concentration of 
MoAb used was based on maximal inhibitory effects on AHH activ-
itya determined in our laboratory (data not shown). The reaction 
was initiated by the addition of 80 nmol of I·C BP in 40 pi of 
acetone. The samples were incubated for 30 min in thedarkat 37°C 
in a Dubnoff metabolic shaker. The reaction was terminated by the 
addition of 1 ml of cold acetone followed by 2 ml of ethyl acetate. 
The mixture was vortexed for 1 min to extract BP metabolites as 
well as unreacted BP into the organic phase. The organic and 
aqueous phases were separated by centrifugation at 1500 rpm for 
1 ~ min. T.he orgamc phase was dried under a stream of nitrogen and 
dissolved In 100 pi of methanol for HPLC analysis. All operations 
were performed under subdued yellow light. 
HPLC Analysis of Formation of BP Metabolites A Waters 
Associates model 204 liquid chromatograph, fitted with a Waters 
Associates radial compression system equipped with a Cis-Radial 
Pak column, was used for the analysis of the radiolabeled metabolite 
mixtures ofBP. Identification of metabolites was based on reference 
standards. The column was eluted at ambient temperature with a 
25-min linear gradient of methanol: water (65: 35, v Iv) at a solvent 
flow rate of 0.6 ml/min. The eluates were monitored at 254 nm. 
fractions of approximately 0.2 ml were collected dropwise, and the 
radioactivity of each fraction was determined on a Packard TriCarb 
460 CO liquid scintillation spectrometer. 
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Electrophoresis of P-450 and Binding to Monoclonal Anti-
bodies Solubilized microsomes were electrophoresed in 7.5% 
(w jv) polyacrylamide gel in the presence of sodium dodecyl sulfate 
as described by Laemmli [29]. The resolved proteins were electro-
phoretically transferred to nitrocellulose sheets (0.45 urn) accord-
ing to the method ofTowbin et al [30] and detected after blocking 
the nonspecific sites with 3% non-fat dry milk and sequential treat-
ment of nitrocellulose sheets with MoAb and anti-mouse goat IgG 
coupled with alkaline phosphatase. The color was visualized as de-
scribed by Park et al [31], the details of which were described ear-
lier (32J. 
RESULTS 
Effect of CCT Application on Epidermal and Hepatic 
Monooxygenase Activities The data shown in Table I indicate 
that topical application of CCT to neonatal rats resulted in signifi-
cant induction of AHH, ECD, and ERD activities at 12 and 24 h 
after treatment. These results are consistent with our earlier obser-
vation that topical application of CCT resulted in significant induc-
tion of monooxygenase activities in epidermis and liver [13J. In 
contrast to these observations, CCT treatment resulted in 31 % and 
35% decreases in P-NPH activity in liver 12 and 24 hr after applica-
tion, respectively. This enzyme activity was not detectable in epi-
dermal microsomes. Earlier it was shown that P-NPH activity is 
principally catalyzed by an ethanol-inducible isozyme ofP-450 [27] 
and this isozyme is present in high amounts in neonatal rat liver 
[33]' These data suggest that CCT induces some isozymes ofP-450 
with overlapping substrate specificity, and that this induction is 
accompanied by a decrease of certain isozyme(s). 
SDS-P AGE and Western Blot Analysis of Epidermal and He-
patic Microsomes Prepared from CCT-Treated Animals 
SDS-PAGE of hepatic microsomes prepared from CCT-treated an-
imals revealed a significant increase in coomassie blue stainable pro-
teins in the M, 50,000 -56,000 region (Fig 1) 24 h after treatment, 
whereas no observable changes in protein migration were seen after 
12 h. These changes were not evident in epidermal microsomes. To 
assess the profile ofp-450 isozymes induced by CCT, Western blot 
analysis of epidermal and hepatic microsomes isolated from CCT-
treated animals was carried out by using highly specific MoAb. 
Immunoblot analysis of epidermal and hepatic microsomes pre-
pared from CCT-treated animals with MoAb 1-7-1 showed strong 
and significant immunoreactivity at the 12 and 24 h treatment pe-
riod in both epidermis and liver (Fig. 2A). No immunoreactivity 
with MoAb 2-66-3 was observed in epidermal microsomes prepared 
from CCT -treated animals, whereas hepatic microsomes prepared 
from these animals showed significantly increased immunoreactiv-
ity with this MoAb (Fig 2B). These data suggest that CCT applica-
tion to neonatal rats resulted in induction ofp-450 isozyme c in liver 
and epidermis and isozyme b in liver. The data in Fig 2C indicate 
that a significant amount of ethanol inducible isozyme P-450 j is 
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Figure 1. SDS-PAGE of epidermal and hepatic microsomes prepared from 
CCT-treated neonatal rats. Forty micrograms of epidermal and 20 JIg of 
hepatic microsomal proteins were applied in each well and separated in 7.5% 
acrylamide-bisacrylamide gel system as described in Materials and Methods. 
present in neonatal rat liver because control liver microsomes 
showed significant immunoreactivity with MoAb 1-98-1. Twelve 
and 24 h after CCT application the hepatic content of isozyme j was 
decreased. These data complement the observed decrease in hepatic 
P-NPH activity (Table I). No immunoreactivity with MoAb 
1-98-1 could be observed in epidermal microsomes prepared from 
either control or CCT -treated animals. 
The Effect of MoAb 1-7-1 and MoAb 2-66-3 on Epidermal 
and Hepatic AIm and ECD Activities The data obtained from 
the Western blots clearly indicate that tissue specific responses oc-
curred in P-450 isozyme induction by CCT. We extended these 
observations by taking advantage of the fact that monoclonal anti-
bodies to purified P-450 isozymes can inhibit the catalytic activity 
of that specific moiety and thereby permit more sensitive assessment 
of the individual isozyme that contributes to the total activity for a 
specific reaction. The data in Fig 3 show that MoAb 1-7-1 signifi-
Table I. Effect of a Single Topical Application of CCT to Neonatal Rats on Epidermal and Hepatic Monooxygenase Activities· 
AHH Activity 
(pmol 3-hydroxy ECD Activity ERD Activity P-NPH Activity 
benzo(a)-pyrenej (pmoI7-hydroxycoumarinj (pmol resorufin/ (nmoI4-N-
Treatment min/mg protein) min/mg protein) min/mg protein) catechol/min/mg protein) 
Epidermis 
Control (acetone) 1.25 ± 0.11 2.15 ± 0.35 0.64 ± 10 ND' 
CCT (12 h) 3.45 ± 0.65b 4.65 ± 0.65b 1.30 ± 0.12b ND' 
CCT (24 h) 11.45 ± 1.32b 15.86 ± 2.62b 5.35 ± 0.65b ND' 
Liver 
Control (acetone) 22 ± 2 52±4 8.5 ± 1.53 0.95 ± 0.25 
CCT (12 h) 45 ± 4b 70±9b 15.65 ± 1.65b 0.65 ± 0.114 
CCT (24 h) 200 ± 8b 212 ± 20b 58.43 ± 5.62b 0.60 ± 0.14d 
• Values represent mean ± SEM oHour determinations. Animals were treated with 200 pi ofCCT (USP) and killed at desired time periods. For each determination, tissues from to 
neonatal rats were pooled, processed, and enzyme activities determined as described in Materiau arid Methods . 
'Significantly higher when compared with controls (p < 0.01) (student'S t-test). 
, NO: not detectable. 
, Significantly lower when compared with controls (p < 0.05) (student'S t-test). 
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Figure 2. Western blot anlaysis of hepatic and epidermal microsomes prepared from CCT treated neonatal rats. A: Immunoreactivity with MoAb 1-7-1; B: 
Immunoreactivity with MoAb 2-66-3; C: Immunoreactivity with MoAb 1-98-1. Forty micrograms of epidermal and 20 J.Lg of hepatic microsomal protein 
were electrophoresed and transferred to nitrocellulose paper overnight at 4 0 C. The nitrocellulose paper was incubated with the MoAb (250 J.Lg/ml) overnight 
at room temperature. The color was developed by incubating the nitrocellulose sheets with a second antibody (goat anti-mouse IgG, phosphatase labelled) and 
reacting further with phosphatase substrate as described in Materials atld Methods. 
candy inhibited AHH and ECD activities in epidermis and liver 
induced by CCT treatment. MoAb 1-7-1 inhibited AHH activity in 
epidermis and liver by 60% and 80%, respectively, whereas the 
inhibition of ECD was only 40% and 60% in epidermis and liver, 
respectively. MoAb 2-66-3 was also inhibitory toward AHH and 
ECD in epidermis and liver; however the effect was only moderate 
(10%) (Fig 3B). These results further support the concept that CCT 
treatment resulted in induction of isozyme c in epidermis and liver, 
and that a part of enzyme activities induced by CCT treatment is 
catalyzed by P-450 isozyme b as well. 
HPLC Analysis ofBP Metabolites and Effects of MoAb 1-7-1 
and MoAb 2-66-3 The effects of MoAb 1-7-1 and 2-66-3 on the 
profile of BP metabolites formed by in vitro incubation of I·C-BP 
by epidermal and hepatic microsomes prepared from CCT -treated 
animals is shown in Fig 4. CCT treatment significantly increased 
the formation of3-0H, 9-0H, 7,8-diol, 9,10-diol and 3,6 quinone 
metabolites of BP. MoAb 1-7-1 was generally more inhibitory as 
compared with MoAb 2-66-3. The inhibition of7 ,S-diol and 3-0H 
BP by MoAb 1-7-1 was more pronounced in epidermis as compared 
with liver. These data further confirm the concept that CCT is a 
mixed inducer of P-450 isozyme(s}. 
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DISCUSSION 
The repeated use of medications containing CCT is associated with 
increased incidence of skin cancer in human populations [34,35]. 
Furthermore, it has been shown that CCT is a potent skin carcino-
gen in experimental animals, and it would appear that the carcino-
genic constituents are mostly P AH and their derivatives. The 
unique susceptibility of skin to carcinogenesis by various P AH and 
the knowledge that metabolism of such chemicals is essential for 
their carcinogenicity have led to extensive studies of xenobiotic 
metabolism in skin. Prior reports from this laboratory have shown 
that epidermis is the major site of xenobiotic metabolism in neonatal 
rat skin [11] , and CCT is a potent inducer of P-450-dependent 
monooxygenase activities in epidermis and liver [13,14]. The data 
in the present study confirm these observations and provide further 
support for the concept that topically applied CCT results in differ-
ential induction of P-450 isozyme(s) in epidermis and liver. 
The P-450 dependent metabolism of xenobiotics may result ei-
ther in the detoxification or activation to toxic, mutagenic, and 
carcinogenic species. Within a tissue the metabolic pathway is usu-
ally dependent on the distribution of the different P-450 isozymes, 
because they display stereoselectivity for both substrate and product 
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Figure 3. MoAb inhibition of hepatic and epidermal AHH and ECD activities induced by CCT in neonatal rats. The animals received a single topical 
application of CCT and were killed 24 h later. Microsomal proteins were incubated with MoAb for 15 min at room temperature. AHH and ECD activities 
were determined by standard fluorometric procedures as described in the text. A : MoAb 1-7-1 ; B: MoAb 2-66-3. 
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Figure ... Effect of MoAb 1-7-1 and MoAb 2-66-3 on epidermal (A) and hepatic (B) BP metabolism induced by a single topical application of CCT, 
Epidermal and hepatic microsomal protein (0,5 mg) from control or CCT treated animals were preincubated with MoAb 1-7-1 and MoAb 2-66-3 for 15 min 
in 0.5 ml at room temperature and transferred to a reaction mixture for assessing BP metabolism. The metabolites were extracted and analyzed by HPLC as 
described in Materials and Methods. 
formation [15]. Thus, specific forms of P-450 can be induced by 
various classes of inducers in a variety of tissues of experimental 
animals and human subjects [9]. An understanding of the distribu-
tion of these isozyme(s) may provide important information con-
cerning human responses to environmental toxins and carcinogens. 
Monoclonal antibodies highly specific to different antigenic sites 
on P-450 isozymes have proven useful in P-450 phenotyping in 
different human and animal tissues [16,17]. In our study, the immu-
noreactivity of epidermal and hepatic microsomes prepared from 
CCT-treated animals with MoAb 1-7-1 on Western blot analysis 
confirms that in these microsomes an epitope specific to MoAb 
1-7-1 is present. Furthermore, the inhibitory effect on AHH activ-
ity in epidermal and hepatic microsomes (60% and 80% in epi-
dermis and liver, respectively) indicates that 80% of the AHH activ-
ity in epidermis and 60% of the AHH activity in liver induced by 
CCT is contributed by a P-450 isozyme that is sensitive to MoAb 
1-7-1. Similarly, ECD activity induced by CCT was inhibited by 
MoAb 1-7-1 (40% and 60% in liver and epidermis, respectively) 
suggesting that this activity is also sensitive to MoAb 1-7-1. P-450 
isozyme c induced by various inducers is capable of metabolizing 
PAH to their activated metabolites in a stereospecific manner [9] . 
CCT treatment resulted in a tenfold increase in the formation of the 
metabolites (e.g., BP 7,S-diol) which are specifically generated by 
P-450 isozyme c. MoAb 1-7-1 inhibited the formation of these 
metabolites, further indicating the greater inducing potential of 
isozyme c by CCT treatment. Western blot analysis of hepatic 
microsomes from CCT -treated animals with MoAb 2-66-3 showed 
a strong immunoprecipitin band, whereas no reactivity was ob-
served in epidermal microsomes. However, MoAb 2-66-3 did in-
hibit AHH and ECD activities in epidermis and liver induced by 
CCT. MoAb 2-66-3 inhibited BP metabolite formation induced by 
CCT to a moderate extent as compared with that of MoAb 1-7-1 , 
This indicates that CCT treatment results in the induction of a 
P-450 isozyme with an epitope sensitive to MoAb 2-66-3. 
CCT treatment also resulted in a time-dependent decrease in 
hepatic P-450 isozyme j, a species known to be induced by ethanol 
and certain other solvents [33]. This is not unusual because certain 
inducers, e.g., Aroclor 1254, 3-MC and polybrominated biphenyl 
congeners have recently been shown to suppress the expression of 
certain constitutive P-4S0 isozyme(s} [36]. It was further suggested 
that a decrease in P-450 isozyme by these compounds may be the 
result of an increase in degradation of the protein and perhaps to a 
competition between constitutive and inducible apocytochromes 
for available heme [36]. Similar mechanisms could be operative 
during the CCT induction response. 
In summary, the data presented in this study suggest that topical 
application of CCT to rats induces epidermal and hepatic P-4S0 
isozymes band c. Cytochrome P-450 isozyme c is known to metab-
olize various precarcinogens to carcinogenic metabolites. For exam-
ple, P-450 isozyme c metabolizes BP and other PAH stereoselec-
tively to their ultimate carcinogenic metabolites. Predominant in-
duction of P-450 isozyme c in liver and epidermis by CCT treat-
ment suggests that its prolonged use may lead to adverse effects not 
only in skin but also in extracutaneous tissues. The differential in-
ducing potential of therapeutic CCT may be related to multiple 
constituents present in CCT or, in part, may be due to unidentified 
factors acting alone or in combination. The specific potential of the 
constituents of CCT to induce other P-450 isozymes will require 
further study. Furthermore, because P-4S0 isozyme composition in 
adult animals, in other species, and in humans are known to be 
different, more detailed studies are needed to define the cause and 
effect relationship. 
The authors are thankJul to Ms. Sandra Evans Jor her help in preparing the manu-
script. 
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